Kenvue Inc. Common Stock (KVUE)
21.65
+0.00 (0.00%)
NYSE · Last Trade: Jun 6th, 4:47 AM EDT
Detailed Quote
Previous Close | 21.65 |
---|---|
Open | - |
Bid | 21.50 |
Ask | 21.80 |
Day's Range | N/A - N/A |
52 Week Range | 17.67 - 25.17 |
Volume | 0 |
Market Cap | - |
PE Ratio (TTM) | - |
EPS (TTM) | - |
Dividend & Yield | 0.8200 (3.79%) |
1 Month Average Volume | 18,273,082 |
Chart
News & Press Releases

US Markets Rebound on Strong Job Data; Tech Stocks Shine as Dollar General Soars
Via Chartmill · June 4, 2025

Looking for the most active stocks in the S&P500 index on Tuesday? Dive into today's session and discover the stocks that are dominating the trading activity and setting the pace for the market.
Via Chartmill · June 3, 2025

Wall Street posted modest midday gains on Tuesday, as investors digested the latest developments in President Donald Trump's trade policy agenda.
Via Benzinga · June 3, 2025

Get insights into the S&P500 index performance on Tuesday. Explore the top gainers and losers within the S&P500 index in today's session.
Via Chartmill · June 3, 2025

Stay tuned for the market movements in the S&P500 index on Tuesday. Check out the gap up and gap down stocks in the S&P500 index during today's session.
Via Chartmill · June 3, 2025

Kenvue Inc. (NYSE: KVUE), maker of consumer health products like Tylenol®, Neutrogena® and Listerine®, today announced it has made the prestigious Fortune 500 list for the first time since becoming a fully independent company. With 2024 full year sales of $15.5 billion, Kenvue is listed at number 281. The company’s debut is a testament to the power of its iconic brands and deep commitment to improving the health and well-being of consumers globally through science-backed, insights-led innovation.
By Kenvue · Via Business Wire · June 2, 2025
New ETF, BOBP, captures opportunities with dynamic rebalancing and quantitative triggers. Its portfolio is constructed using behavioral finance and statistical patterns.
Via Benzinga · May 27, 2025
Activist investor Dan Loeb's Third Point LLC acquired a significant stake in consumer health company Kenvue Inc. in Q1 2025.
Via Benzinga · May 27, 2025
KENVUE INC (NYSE:KVUE) shows strong technicals and a promising breakout setup, supported by a high technical rating and consolidation pattern. A potential entry above $24.45 offers a defined risk-reward scenario.
Via Chartmill · May 24, 2025
Via The Motley Fool · May 23, 2025
For buy-and-hold investors looking for some quality names to navigate a turbulent market, here are three stocks to consider
Via MarketBeat · May 22, 2025
Kenvue Inc. (NYSE: KVUE), the maker of iconic brands such as Neutrogena®, Listerine®, Aveeno®, and Tylenol®, today announced the Company’s participation in Deutsche Bank’s dbAccess Global Consumer Conference in Paris, France. Thibaut Mongon, Chief Executive Officer, Amit Banati, Chief Financial Officer, and Carlton Lawson, Group President, Europe, Middle East and Africa & Latin America will participate in a fireside chat on Tuesday, June 3, 2025, at 6:00 a.m. Eastern Time / 12:00 p.m. Central European Time. A live webcast of the session will be available on investors.kenvue.com and a replay will be available on the website following the event.
By Kenvue · Via Business Wire · May 21, 2025
Third Point LLC, led by Dan Loeb, sold stakes in top stocks during Q1 of 2025 amid tariff concerns. Also made significant new additions and increases.
Via Benzinga · May 16, 2025
Kenvue Inc. (NYSE: KVUE), the maker of iconic brands such as Neutrogena®, Listerine®, Aveeno®, and Tylenol®, today announced its global community engagement efforts in celebration of Kenvue Cares Week, the company’s signature annual volunteer initiative part of its Healthy Lives Mission. Kenvue Cares Week is a testament to the strong Kenvue commitment to advance the well-being of people and our planet, giving back through volunteerism, and delivering meaningful, measurable impact in local communities.
By Kenvue · Via Business Wire · May 14, 2025
Via Benzinga · May 9, 2025
Before Kenvue and Johnson & Johnson, Ruh was at PepsiCo for 17 years.
Via Stocktwits · May 8, 2025
Kenvue beat Q1 sales estimates and updated its 2025 forecast as it manages foreign exchange impacts, tariffs, and leadership changes.
Via Benzinga · May 8, 2025
The company estimates adjusted diluted earnings per share for FY25 to be about flat compared to FY24, when it reported a profit of $1.14 per share.
Via Stocktwits · May 8, 2025
Curious about the S&P500 stocks that are showing activity before the opening bell on Thursday?
Via Chartmill · May 8, 2025
Kenvue Inc. (NYSE: KVUE) today announced financial results for the first quarter ended March 30, 2025.
By Kenvue · Via Business Wire · May 8, 2025
Kenvue Inc. (NYSE: KVUE), today announced the appointment of Amit Banati as the Company’s Chief Financial Officer, effective May 12, 2025. He will be responsible for overseeing the Finance and Strategy functions, supporting initiatives aimed at accelerating profitable growth and delivering value to shareholders. Following a thorough and thoughtful search process, Mr. Banati will succeed Paul Ruh, who will remain with the Company for a brief period to help ensure a smooth transition.
By Kenvue · Via Business Wire · May 8, 2025
U.S. stocks traded mixed at midday Wednesday, as investors remained cautious ahead of the Federal Reserve’s upcoming policy decision, with Chair Jerome Powell set to speak at 2:30 p.m. ET.
Via Benzinga · May 7, 2025